SEC Form 4 · accession 0001209191-15-078404

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 2, 2015

Accepted (ET)

Nov 4, 2015 · 4:15 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Nov 2, 2015	M	20,000	$53.85	A	25,265	D
Common Stock^F2,F3	Nov 2, 2015	S	900	$123.66	D	24,365	D
Common Stock^F2,F4	Nov 2, 2015	S	700	$125.09	D	23,665	D
Common Stock^F2,F5	Nov 2, 2015	S	9,592	$125.98	D	14,073	D
Common Stock^F2,F6	Nov 2, 2015	S	6,708	$126.91	D	7,365	D
Common Stock^F2,F7	Nov 2, 2015	S	2,100	$127.62	D	5,265	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F8	$53.85	Nov 2, 2015	M	20,000	D	—	May 31, 2021	Common Stock	20,000	0	D

F1Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1.
F2Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $123.66 (range $123.40 to $124.27).
F4Open market sales reported on this line occurred at a weighted average price of $125.09 (range $124.44 to $125.38).
F5Open market sales reported on this line occurred at a weighted average price of $125.98 (range $125.44 to $126.43).
F6Open market sales reported on this line occurred at a weighted average price of $126.91 (range $126.44 to $127.43).
F7Open market sales reported on this line occurred at a weighted average price of $127.62 (range $127.46 to $127.85).
F8Fully vested.